{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:53Z","timestamp":1787009453409,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["flzh202119"],"award-info":[{"award-number":["flzh202119"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Bethune Charitable Foundation","award":["flzh202119"],"award-info":[{"award-number":["flzh202119"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to explore the relationship between irradiation of lymphocyte-related organs at risk (LOARs) and lymphopenia during definitive concurrent chemoradiotherapy (dCCRT) for esophageal squamous cell carcinoma (ESCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Cases of ESCC patients who received dCCRT from 2 prospective clinical trials were identified. To find its correlation with survival outcomes, grades of absolute lymphocyte counts (ALCs) nadir during radiotherapy were recorded following COX analysis. Associations of lymphocytes at nadir and dosimetric parameters including relative volumes of spleen and bone marrow receiving 0.5, 1, 2, 3, 5, 10, 20, 30, and 50Gy (V0.5, V1, V2, V3, V5, V10, V20, V30, and V50), and effective dose to circulating immune cells (EDIC) were examined by logistic risk regression analysis. The cutoffs of dosimetric parameters were determined by the receiver operating characteristic curve (ROC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 556 patients were included. The incidences of grades 0, 1, 2, 3, and 4 (G4) lymphopenia during dCCRT were 0.2%, 0.5%, 9.7%, 59.7%, and 29.8%, respectively. Their median overall survival (OS) and progression-free survival (PFS) time were 50.2 and 24.3 months, respectively; the incidence of local recurrence and distant metastasis were 36.6% and 31.8%, respectively. Patients once suffering from G4 nadir during radiotherapy had unfavorable OS (HR, 1.28; P = .044) and a higher incidence of distant metastasis (HR, 1.52; P = .013). Furthermore, patients with EDIC \u22648.3Gy plus spleen V0.5 \u226411.1% and bone marrow V10 \u226433.2% were strongly associated with lower risk of G4 nadir (OR, 0.41; P = .004), better OS (HR, 0.71; P = .011) and lower risk of distant metastasis (HR, 0.56; P = .002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Smaller relative volumes of spleen V0.5 and bone marrow V10 plus lower EDIC were jointly prone to reduce the incidence of G4 nadir during definitive concurrent chemoradiotherapy. This modified therapeutic strategy could be a significant prognostic factor for survival outcomes in ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad109","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T18:04:41Z","timestamp":1684951481000},"page":"e645-e652","source":"Crossref","is-referenced-by-count":13,"title":["Less Irradiation to Lymphocyte-Related Organs Reduced the Risk of G4 Lymphopenia in Esophageal Cancer: Re-Analysis of Prospective Trials"],"prefix":"10.1093","volume":"28","author":[{"given":"Ihsuan","family":"Tseng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences , Shenzhen , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Enhance Human Health through Pharma Technology Innovation , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Public Health, Shanghai Medical College of Fudan University , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Pan","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences , Shenzhen , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-2278","authenticated-orcid":false,"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology , Shanghai , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"6","key":"2023080322074555500_CIT0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2023080322074555500_CIT0002","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","article-title":"Assessing the interactions between radiotherapy and antitumour immunity","volume":"16","author":"Grassberger","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2023080322074555500_CIT0003","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"2023080322074555500_CIT0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2023080322074555500_CIT0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"2023080322074555500_CIT0006","doi-asserted-by":"crossref","first-page":"1758835920926822","DOI":"10.1177\/1758835920926822","article-title":"A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2023080322074555500_CIT0007","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fonc.2020.00997","article-title":"Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2023080322074555500_CIT0008","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1002\/onco.13533","article-title":"Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: association with dosimetric parameters and patient outcomes","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"issue":"17","key":"2023080322074555500_CIT0009","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1002\/cam4.4131","article-title":"Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Medicine (Malden, MA)"},{"issue":"5","key":"2023080322074555500_CIT0010","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.21037\/jtd.2020.03.93","article-title":"Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer","volume":"12","author":"Newman","year":"2020","journal-title":"J Thorac Dis"},{"key":"2023080322074555500_CIT0011","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.2147\/CMAR.S297010","article-title":"The impact of lymphopenia and dosimetric parameters on overall survival of esophageal cancer patients treated with definitive radiotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"2023080322074555500_CIT0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.radonc.2019.12.008","article-title":"Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer","volume":"152","author":"Anderson","year":"2020","journal-title":"Radiother Oncol"},{"issue":"6","key":"2023080322074555500_CIT0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.21873\/invivo.11409","article-title":"Spleen dose\u2013volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer","volume":"32","author":"Saito","year":"2018","journal-title":"In Vivo"},{"issue":"5","key":"2023080322074555500_CIT0014","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2023080322074555500_CIT0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother Oncol"},{"issue":"20","key":"2023080322074555500_CIT0016","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023080322074555500_CIT0017","doi-asserted-by":"crossref","first-page":"e220120","DOI":"10.1001\/jamanetworkopen.2022.0120","article-title":"Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: a randomized clinical trial","volume":"5","author":"Ai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"24","key":"2023080322074555500_CIT0018","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023080322074555500_CIT0019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2023080322074555500_CIT0020","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2005.11.022","article-title":"Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors","volume":"64","author":"El","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023080322074555500_CIT0021","doi-asserted-by":"crossref","first-page":"01200912009","DOI":"10.1088\/1742-6596\/949\/1\/012009","article-title":"Multicollinearity and regression analysis","volume":"949","author":"Daoud","year":"2017","journal-title":"J Phys Conf Ser"},{"issue":"1","key":"2023080322074555500_CIT0022","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.prro.2019.07.010","article-title":"Prediction of severe lymphopenia during chemoradiation therapy for esophageal cancer: development and validation of a pretreatment nomogram","volume":"10","author":"van Rossum","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2023080322074555500_CIT0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14338\/IJPT-17-00033.1","article-title":"Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation","volume":"4","author":"Fang","year":"2018","journal-title":"Int J Part Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e645\/51034799\/oyad109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e645\/51034799\/oyad109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T18:09:11Z","timestamp":1691086151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/e645\/7191662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad109","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,6,7]]}}}